Amicus Therapeutics Inc (FOLD)

9.46 +0.10 (+1.07%) USD  |  NASDAQ  |  Jan 08, 16:00
9.455 0.00 (0.00%) After-Hours: 20:00
More

Amicus Therapeutics SG&A Expense (Quarterly): 75.11M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for FOLD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Tonix Pharmaceuticals Holding Corp 7.707M
Immuneering Corp 4.014M
Halozyme Therapeutics Inc 41.24M
Alnylam Pharmaceuticals Inc 220.99M
Insmed Inc 118.93M